Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT03500133 Recruiting - Clinical trials for Pediatric Hodgkin's Disease

Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.

LHGALOP2017
Start date: October 6, 2017
Phase: Phase 4
Study type: Interventional

This trial proposes a therapy for pediatric Hodgkin lymphoma with the objective of achieving high levels of long lasting complete remission with less risk of late effects. Patients of both genders, between 2 and 18 years, with newly diagnosed classical Hodgkin lymphoma are admitted. Initial staging provides a stratification in three groups: low, intermediate and high risk. An initial set of two chemotherapy courses is administered to all cases after which a new disease assessment is performed. According to disease response a final therapy group is assigned. Rapid early responders benefit from less chemotherapy. At the end of chemotherapy, radiotherapy is delivered only to patients who do not achieve a complete response. Thus therapy is tailored to initial extension and disease responsiveness. Complete responders at the end of chemotherapy do not receive radiotherapy. Those who are in partial remission receive low dose (30Gy) involved node radiotherapy. Stable or progressive disease at any moment is assumed as a trial failure and new therapeutic strategies are offered to patients off protocol. Chemotherapy is based upon regimes with well known effectiveness in Hodgkin lymphoma. (i.e. ABVD: doxorubicin, bleomycin, vinblastine and dacarbazine and ESHAP: Etoposide, methyl prednisolone, citarabine and cisplatinum). The schedules are delivered with low cumulative drug doses and avoiding the use of toxic alkylating agents. Risks of secondary leukemia and infertility are thus minimized. Doxorubicin and bleomycin do not achieve cumulative doses that may expose to significant risk of heart or lung damage. Radiotherapy reduction avoids late radiation sequels. This clinical study proposes a therapeutic approach based on chemotherapy that do not expose to high cumulative toxic doses. Therapy is tailored according to initial risk assessment and disease responsiveness. Those who achieve a complete response to chemotherapy do not receive additional radiotherapy, thus avoiding further late effects.

NCT ID: NCT03498612 Not yet recruiting - Follicular Lymphoma Clinical Trials

Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

Start date: May 16, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating participants with B-cell non-Hodgkin lymphoproliferative diseases that have not been treated. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread.

NCT ID: NCT03497533 Recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19

Trident19-H
Start date: May 10, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm, open-label, single-center, phase 1/2 study, to determine the safety and efficacy of TriCAR-T-CD19, an autologous tri-functional anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in refractory/Relapsed Non-Hodgkin Lymphoma (NHL).

NCT ID: NCT03496779 Not yet recruiting - Clinical trials for Refractory Peripheral T-Cell Lymphoma

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Start date: April 2018
Phase: Phase 2
Study type: Interventional

This study is an open label, multicenter phase 2 study. The primary objective of the study is to determine the efficacy of brentuximab vedotin in patients treated by gemcitabine for relapsed or refractory peripheral T-cell lymphoma in term of overall response rate assessed after 4 cycles of treatment according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).

NCT ID: NCT03495960 Not yet recruiting - Clinical trials for Primary Central Nervous System Lymphoma

Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

FIORELLA
Start date: April 30, 2018
Phase: Phase 2
Study type: Interventional

Primary central nervous system lymphomas are rare aggressive malignancies, usually treated in two steps: an induction phase (where a combination of chemotherapy is given) followed by a consolidation phase (where patients usually receive one of the following: whole-brain irradiation, chemotherapy supported by autologous stem-cell transplantation, other type of chemotherapy, or are just observed). The feasibility of this overall strategy, for several reasons, is limited in elderly patients . This study involves patients aged ≥70 years. The more fit patients will receive the standard chemotherapy combination (high-dose methotrexate, procarbazine and rituximab) as induction. Responding patients will receive either procarbazine or lenalidomide as maintenance therapy; the aim is to evaluate the efficacy of these two drugs. The more fragile patients will receive a less aggressive therapy consisting of concomitant whole-brain radiotherapy, temozolomide and rituximab as induction therapy, followed by temozolomide as maintenance treatment; the aim is to evaluate the efficacy of this combination of treatment.

NCT ID: NCT03495713 Recruiting - Hodgkin Lymphoma Clinical Trials

RADVAX™ FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS

Start date: March 2, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase II single-arm, single-site, open label clinical trial with r/r HL patients, aimed to determine whether a RadVax approach using low-dose RT added to nivolumab can improve response among patients who do not achieve a CR to nivolumab alone. The long-term goal is to develop an effective regimen for r/r HL patients.

NCT ID: NCT03494296 Recruiting - Lymphoma Clinical Trials

A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL

Start date: March 1, 2018
Phase:
Study type: Observational

Decitabine is a cytosine analogue and is a specific DNA methyltransferase (DNMT) inhibitor. It directly inhibits DNMT by phosphorylating DNA and inhibits DNMT, thereby reversing DNA methylation and inducing tumor cells to Normal cell differentiation or induction of tumor cell apoptosis.Diffuse large B-cell lymphoma (DLBCL) is the most common pathological type in non-Hodgkin's lymphoma. The first-line chemotherapy regimen using Rituximab+Cyclophosphamide+Doxorubicin +Vincristine+Bonisone(R-CHOP)significantly increases the remission rate and disease-free survival of patients with DLBCL, but it is difficult to partially relapse. Long-term remission and survival rates in treating patients are not satisfactory.Due to the greater cardiac toxicity of adriamycin, more patients can not be uncomfortable, so the COP program is also widely used in patients with DLBCL, and achieved a good response rate.In 2008, the FDA had approved decitabine for the demethylation treatment of Myelodysplastic syndrome(MDS). Over the years, good initial remission rates and better long-term survival rates have been achieved in patients with MDS.There are also a variety of clinical trials of decitabine for patients with solid tumors that have achieved significant clinical efficacy.Due to the high side effects of high-dose decitabine, patient tolerance is poor. Therefore, the purpose of this study was to evaluate the efficacy and safety of low-dose decitabine combined with Cyclophosphamide+Vindesine+Bonisone(COP) regimen (D-COP) 4-6 course of treatment for relapsed and refractory diffuse large B-cell lymphoma.

NCT ID: NCT03494179 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Study to Investigate ICP-022 in Chinese Patients With R/R Mantle Cell Lymphoma (MCL)

Start date: April 2, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The phase I/II clinical study is to investigate the safety, tolerability and pharmacokinetics/ pharmacodynamics of ICP-022.

NCT ID: NCT03492775 Recruiting - Clinical trials for Indolent Non-hodgkin Lymphoma

First Line Therapy of Advanced Stage Follicular Lymphoma in Patients Not Eligible for Standard Immunochemotherapy

GABe2016
Start date: December 12, 2017
Phase: Phase 3
Study type: Interventional

The objective of this study is to test whether a combined OBINUTUZUMAB/bendamustine therapy is superior to single agent OBINUTUZUMAB in medically non-fit, 'compromised' patients in terms of anti-lymphoma activity (primary objective), side effects, and quality of life. For the assessment of the anti-lymphoma activity the "event free survival (EFS)" will be applied as primary endpoint. EFS is defined as the time from the day of randomization to the date of first documented disease progression, death by any cause, or institution of a new anti-lymphoma treatment.

NCT ID: NCT03492125 Not yet recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Study Of The Selective PKC-β Inhibitor MS- 553

Start date: April 30, 2018
Phase: Phase 1
Study type: Interventional

A Phase I Dose-Escalation Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma